Institutional Review Boards
4520 Dixie Rd
Mississauga, ON L4W 1N2 CANADA
Business: 905-238-0599
Fax: 905-238-0682
E-mail: bd@allied-research.com
Web Site: www.allied-research.com
Contact: Marc Routhier
421 S Lynnhaven Rd Ste 101
Virginia Beach, VA 23452
Business: 757-631-2114
Fax: 757-631-2115
E-mail: dholm@arkios.com
Web Site: www.arkios.com
Contact: Dawn Holm
9628 Campo Rd Ste S
San Diego, CA 91977
Business: 619-469-0108
Fax: 619-469-4108
E-mail: michele@aspire-irb.com
Web Site: www.aspire-irb.com
Contact: Michele R. Baptista CIP
2701 Kent Ave
West Lafayette, IN 47906
Toll-free: 800-845-4246
Business: 765-463-4527
Fax: 765-497-1102
E-mail: basi@bioanalytical.com
Web Site: www.bioanalytical.com
Contact: Janna Chambers
2525 Camino del Rio South 300
San Diego, CA 92108
Business: 619-282-9997
E-mail: mailbox@biomedirb.com
Web Site: www.biomedirb.com
Contact: Richard M. Sullivan MD
7063 Columbia Gateway Drive Ste 110
Columbia, MO 21046-3403
Business: 410-884-2900
Fax: 410-997-5959
E-mail: info@irbinfo.com
Web Site: www.chesapeakeirb.com
1075 Cheshire Circle
Danville, CA 94506
Business: 925-648-1510
Fax: 925-648-1520
E-mail: info@clinfosource.com
Web Site: www.clinfosource.com
31 Monhegan Ave
Wayne, NJ 07470
Business: 973-696-0824
Fax: 973-696-8541
E-mail: info@clinicalrdservices.com
Web Site: www.clinicalrdservices.com
Contact: Bruce A. Lepp
2 South Pointe Drive Ste 220
Lake Forest, CA 92630
Business: 949-218-9969
Fax: 949-218-9807
E-mail: sales@coastirb.com
Web Site: www.coastirb.com
Contact: Todd McDaniel
1828 L St NW Ste 250
Washington, DC 20036
Business: 202-448-6150
Fax: 202-448-6188
E-mail: sbrink@consentsolutions.com
Web Site: www.consentsolutions.com
Contact: Susan Brink
118 MacKenan Dr Ste 400
Cary, NC 27511
Toll-free: 888-303-2224
Fax: 919-654-7210
E-mail: jsodrel@cgirb.com
Web Site: www.cgirb.com
Contact: Jennifer Sodrel
332 Santa Fe Dr Ste 110
Encinitas, CA 92024
Business: 760-943-6700
Fax: 760-632-4292
E-mail: fawad@coreorthopaedic.com
Web Site: www.coreorthopaedic.com
Contact: Farouk A. Awad
DR. OESTREICH + PARTNER, RESEARCH+MARKETING IN MEDICINE_PHARMACY GMBH
Hansaring 102-104
Cologne, 50670 GERMANY
Business: 49-221-9128710
Fax: 011-49-221-9128711
E-mail: woe@oandp-cro.com
Web Site: www.oandp-cro.com
Contact: Wolfgang Oestreich MD
1255 Transcanada Hwy Ste 310
Dorval, QC H9P 2V4 CANADA
Business: 514-421-0442
Fax: 514-421-1142
E-mail: jparente@ethicaclinical.ca
Web Site: www.ethicaclinical.ca
Contact: Janice E. Parente
6350 Quadrangle Dr
Chapel Hill, NC 27517
Business: 919-967-1111
Fax: 919-967-1145
E-mail: sales@healthdec.com
Web Site: www.healthdec.com
Contact: Jack Huisman
6088 Main Street, PO Box 138
Miamiville, OH 45147
Toll-free: 800-785-2693
Business: 513-831-3114
Fax: 513-831-1217
E-mail: info@hill-top.com
Web Site: www.hill-top.com
Contact: Bryan Reynolds
8 av des Grandes-Communes, Petit-Lancy
Geneva, CH-1213 SWITZERLAND
Business: 41-22-792 40 44
Fax: 011-41-22-793 00 71
Web Site: www.hpmgeneva.ch
100 Tamel Plaza Ste 158
Corte Madera, CA 94925
Business: 415-485-0717
Fax: 415-485-0328
Web Site: www.irb-irc.net
3001 S Lamar Blvd Ste 210
Austin, TX 78704
Business: 512-326-3001
Fax: 512-326-3446
E-mail: integreview@integreview.com
Web Site: www.integreview.com
Contact: Lynn Meyer
2350 Mission College Blvd Ste 700
Santa Clara, CA 95054
Business: 408-330-9400
Fax: 408-330-9410
E-mail: robmuir@majaro.com
Web Site: www.majaro.com
Contact: Rob Muir
710 N Lake Shore Dr 10th Flr
Chicago, IL 60611
Business: 312-503-7952
Fax: 312-503-1505
E-mail: nccr@northwestern.edu
Web Site: www.nccr.northwestern.edu
Contact: Mary Sullivan
Unit 1 Rycote Lane Farm, Rycote Lane, Milton Common
Oxon, OX9 2NZ UNITED KINGDOM
Business: 44-1844-279-600
Fax: 44-1844-279-602
E-mail: enquiries@orsoxford.co.uk
Web Site: www.oxreg.com
Contact: George Overend
1616 N Fort Myer Dr Ste 1430
Arlington, VA 22209
Business: 703-276-0178
Fax: 703-276-0069
E-mail: info@peri.org
Web Site: www.peri.org
Bahnhofstrasse 20, PO Box 173
Thalwil, 8800 SWITZERLAND
Business: 41-44-723-59-59
Fax: 011-41-44-723-59-60
E-mail: info@pharmapart.com
Web Site: www.pharmapart.com
Contact: Brian Rees
4801 Amber Valley Pkwy, PO Box 9358 (58106)
Fargo, ND 58105
Business: 701-239-4750
Fax: 701-239-4955
Web Site: www.pracs.com
4709 Creekstone Drive
Durham, NC 27703
Business: 919-998-2000
Fax: 919-998-2571
E-mail: qtrn.information@quintiles.com
Web Site: www.quintiles.com
Contact: Paul Spreen
Merthyr Tydfil Ind Park, Cardiff Rd
Merthyr Tydfil, South Wales CF48 4DR UNITED KINGDOM
Business: 44-1443-690977
Fax: 011-44-1443-692499
E-mail: alan.woodward@simbec.co.uk
Web Site: www.simbec.co.uk
Contact: Alan J. Woodward
John Eccles House Robert Robinson Avenue
The Oxford Science Park, Oxfordshire OX4 4GP UNITED KINGDOM
Business: 44-1865-389138
Fax: 011-44-1865-389139
E-mail: sales@studybuilder.com
Web Site: www.studybuilder.com
Contact: Michael Johnson
7501 Wisconsin Ave Ste 705
Bethesda, MD 20814
Business: 240-644-0420
Fax: 240-644-0421
E-mail: info@unitedbiosource.com
Web Site: www.unitedbiosource.com
Contact: Patrick Lindsay
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.